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OBJECTIVES: Vaginal atrophy and breast cancer are common conditions in postmenopausal women and
tamoxifen is the standard endocrine treatment for hormone-sensitive tumors. The present study aimed to assess
the effect of tamoxifen on Ki-67 protein expression in the vaginal epithelium of castrated rats.
MATERIAL AND METHODS: Forty Wistar-Hannover adult, virgin, castrated rats were randomly divided into two
groups, group I (control, n=20) and group II (tamoxifen, n=20), receiving 0.5 ml of propylene glycol and 250 mg
of tamoxifen diluted in 0.5 ml of propylene glycol, respectively, daily by gavage for 30 days. On the 31st day, the
rats were euthanized and their vaginas were removed and fixed in 10% buffered formalin for the
immunohistochemical study of Ki-67 protein expression. Data were analyzed by the Levene and Student’s
t tests (po0.05).
RESULTS: The mean index of Ki-67 expression in the rat vagina of groups I and II was 4.04±0.96 and 26.86±
2.19, respectively (po0.001).
CONCLUSIONS: According to the results of the present study, tamoxifen, at the dose and treatment length used,
induced a significant increase in the cell proliferation of the vaginal mucosa in castrated rats, as evaluated by
Ki-67 protein expression.
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’ INTRODUCTION
The number of postmenopausal women worldwide has
increased due to improved access to healthcare services, better
living conditions and increased life expectancy. Women spend
approximately one-third of their lifetime in the postmenopausal
period and may become vulnerable to chronic degenerative
diseases such as breast cancer (1). Breast cancer is the most
common malignancy among women, particularly in the
postmenopausal period. In Brazil, breast cancer is an important
cause of cancer-related death, with approximately 57,120 new
cases of breast cancer and 13,345 deaths from this disease
estimated for the year 2014 (2-4). However, the survival of
women with breast cancer has increased in the last few years,
especially due to early diagnosis and to modes of systemic
treatment. Endocrine treatment is the main treatment for
women with estrogen receptor-positive breast cancer (5).
Tamoxifen is a first-generation selective estrogen receptor
modulator (SERM) approved by the US Food and Drug
Administration (FDA) for primary chemotherapy and adjuvant
treatment of women with breast cancer (6).
The mechanism of action of tamoxifen has not been fully
elucidated. However, because it interacts particularly with
estrogen receptors, tamoxifen may have an effect on symptoms
due to hypoestrogenism, such as vaginal atrophy and dyspar-
eunia, which are common in postmenopausal women with
breast cancer (7-11). The vaginal mucosal epithelium has both
alpha and beta estrogen receptors, with decreasing beta receptor
levels after menopause (10). As shown by some authors,
tamoxifen exerts both estrogenic and antiestrogenic effects in
the vaginal epithelium of castrated rats (12). Nevertheless, other
authors, by using indirect methods such as vaginal cytology,
have shown that the drug exerts an estrogenic action on the
vaginal mucosa of postmenopausal women (13-15). The study of
drug effects on the vaginal tissue of postmenopausal women is
not possible due to ethical reasons. As few studies have
investigated the direct effect of tamoxifen on the vaginal
epithelium of castrated rats, the present study was conducted.DOI: 10.6061/clinics/2016(02)07
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’ MATERIAL AND METHODS
Animals
This study was approved by the Animal Experimentation
Ethics Committee (AEEC) of the Universidade Federal do Piauı´
(UFPI), complying with the guidelines of the Brazilian College
of Animal Experimentation (COBEA). Forty Wistar-Hannover
virgin female rats obtained from the animal laboratory of the
School of Veterinary Science at UFPI were used. The animals
were housed inside a plastic cage with a metallic lid. Five
animals per cage were kept since birth with free access to
filtered water and rodent chow (SUPPRALABs, São Paulo,
Brazil). Ambient conditions were controlled by a 12-hour light/
dark cycle, with the lights switched on from 7 a.m. to 7 p.m. Air
conditioning maintained the temperature between 20 and 25oC.
The animals were randomly divided into two groups: group I
(control, n=20) and group II (tamoxifen, n=20). At 90 days of
age, the rats in groups I and II weighing an average of 231.5±
20.85 g and 231.2±21.74 g (p=0.9647), respectively, were
castrated to eliminate gonadal sex steroid production through
a dorsal paravertebral incision under anesthesia with 60 mg/kg
ketamine and 4 mg/kg midazolam. Twenty-one days later,
cytologic examination of Papanicolaou-stained vaginal smears
was performed to characterize a decreased estrogen status,
which was confirmed by the absence of cell maturation and a
predominance of basal cells in all the animals. Group I rats
(control) began to receive 0.5 ml/animal/day of propylene
glycol (placebo) and Group II rats (experimental) received
250 mg/animal/day of tamoxifen citrate diluted in 0.5 ml of
propylene glycol. The placebo and tamoxifen were continu-
ously administered for 30 days, both at the same hour of the
day, using a metal tube appropriate for gavage. On the 31st
day, the rats from both groups were sacrificed and their vaginas
were removed through a longitudinal abdominal incision for
histologic and immunohistochemical studies.
Ethics Approval
This study was approved by the Animal Experimentation
Ethics Committee (AEEC) of the Universidade Federal do
Piauí (UFPI).
Ki-67 Immunohistochemistry
For the immunohistochemical study of Ki-67 expression,
tissue specimens were fixed in 10% buffered formalin for a
12-24-hour period and then cut into 5-mm-thick sections. The
sections were processed and stained with hematoxylin-eosin,
deparaffinized in xylene for 5 minutes, dehydrated in absolute
ethanol and washed in buffered saline solution at pH 7.4 for
5 minutes (16). Endogenous peroxidase activity was blocked
with 3% hydrogen peroxide (H202) diluted in a buffered
solution for 5 minutes. After epitope retrieval, the tissue
samples were incubated with primary mouse anti-Ki-67
monoclonal antibody (clone MIB-5/Dako/1:100) in a refrig-
erator at approximately 4oC overnight. Subsequently, the
samples were washed with buffered saline solution and
incubated for 45 minutes in the NovoLink Polymer detection
system. Color development was accomplished by incubating
all the tissue samples in 3-3-diaminobenzidine tetrahy-
drochloride solution at a concentration of 1 mg/ml in a
Tris-buffered solution, with a hydrogen peroxide solution
used as a substrate, for 5 minutes. Subsequently, the tissues
were counterstained with Harris’ hematoxylin or methyl
green for 5 minutes, followed by dehydration in ethanol and
xylene baths. After the procedure, the slides were examined
to quantify the results. Cells expressing Ki-67 protein were
identified by the dark brown color of their nuclei.
Quantitative method
Ki-67 expression was quantified by two observers who were
blinded to the group identification. Stained images were assessed
by using a Nikon E400 light microscope connected to a Samsung
color digital video camera, model SCC-131. The video camera
captured and transmitted the image to a computer equipped
with ImageLabs software, version 2.3, which was developed
by Softium Informática Ltda (São Paulo, Brazil) for image
analysis. To evaluate Ki-67 expression, 500 vaginal epithelial
cells were counted on each slide whether or not the cells were
stained with anti-Ki-67 MIB-5 antibody. A total magnifica-
tion of  400 was used to examine the slides. Cell counting
was initiated at the site of greatest Ki-67 antigen expression.
In each case, the percentage of stained cells was obtained by
the ratio between the number of cells with stained nuclei and
the total number of cells multiplied by 100.
Statistical Analysis
To evaluate group homogeneity relative to weight,
Student’s t test was used for independent samples. Variance
analysis of the percentages of nuclei stained with anti-Ki-67
was conducted using the Levene and Student’s tests (17). The
significance level was set at po0.05.
’ RESULTS
By light microscopy, cytologic examination of the vaginal
epithelial cells of control group animals showed the absence of
cell maturation and a predominance of basal cells, while
tamoxifen-treated animals showed predominant cell maturation.
Compared with control group animals, castrated female rats
treated with tamoxifen showed a higher concentration of nuclei
stained with anti-Ki-67 (Figure 1). The mean percentage of
MIB-5-stained nuclei in the vaginal mucosa of group I (control)
and group II (tamoxifen) rats was 4.04±0.96 and 26.86±2.19,
respectively (po0.001) (Table 1). The boxplot illustrates the
median Ki-67 expression in the vaginal mucosal cells of animals
from the control and tamoxifen groups (Figure 2).
’ DISCUSSION
In the present study, tamoxifen at a dose of 250 mg/
animal/day administered for 30 days significantly increased
proliferation of the vaginal mucosa in castrated rats, as
evaluated by Ki-67 protein expression. The animals received
tamoxifen orally (gavage) to mimic the administration route
used in women. Furthermore, according to several authors
that have studied different routes of administration, the oral
route led to higher serum and tissue levels of tamoxifen,
thereby increasing the bioavailability of tamoxifen (18,19).
Tamoxifen was diluted in propylene glycol, a neutral,
colorless and odorless vehicle, allowing for the dilution
and administration of predefined doses (20,21).
However, the tamoxifen dose in animal experimental
studies is not easy to standardize because rats have a faster
metabolism than humans. Equal-weight doses may not
reproduce the serum levels and effects of tamoxifen in
women (22). Dos Santos et al. (21), who studied the morpho-
metry of the urethra in castrated rats given a 250 mg/day
tamoxifen dose for 30 days, observed that tamoxifen was
capable of increasing the uterine weight and the thickness of
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the distal urethral epithelium. Thus, we used a dose of
250 mg/animal/day in this study because it could mimic the
effects of tamoxifen on women undergoing breast cancer
treatment (22).
Friedrich et al. (13) studied the influence of tamoxifen on
vaginal epithelial maturation in postmenopausal women and
demonstrated an apparent increase in vaginal epithelial
maturation. In another study, Friedrich et al. (14) investi-
gated the effects of tamoxifen on vaginal and cervical
epithelial proliferation in postmenopausal women with
breast cancer and found an apparent increase not only in
the incidence of metaplasia and hyperplasia of endocervical
cells but also in vaginal epithelial maturation. According to
Bertolissi et al. (15), tamoxifen exerts an early and persistent
estrogenic effect on the vaginal epithelium during the first
year of therapy in postmenopausal women with breast
cancer.
Nevertheless, Berg and Dunfee (23) showed that post-
menopausal women with high levels of squamous epithelial
cell maturation were 15 times more likely than women in
the same age group exhibiting an atrophic pattern to have
coexistent endometrial adenocarcinoma because tamoxifen
acts in accordance with circulating estrogen levels. Therefore,
when estrogen levels are low, tamoxifen behaves as an
agonist and may cause endometrial cancer. In contrast,
during the premenopausal period, when estrogen levels are
higher, tamoxifen appears to have an antiestrogenic action in
this tissue (24). Thus, the agonist or antagonist action of
SERMs in the endometrium may depend on circulating
estrogen levels (25,26).
The results of the present study indicate that tamoxifen, at
the dose and length of treatment used in this study, induced
a significant increase in cell proliferation of the vaginal
mucosa in castrated rats, as evaluated by Ki-67 protein
expression. Thus, the assessment of cell proliferation in the
vagina of castrated rats, used to as a mimic of postmeno-
pausal women, revealed that tamoxifen displayed partially
estrogenic action on the vaginal mucosa of these animals.
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